Index changes put Abbott Laboratories in focus
Abbott Laboratories (ABT) has just been added to the Russell 1000 Dynamic Index after being removed from the Russell Top 50 Index, a reshuffle that draws attention to how investors are positioning around the stock.
These index moves come as Abbott Laboratories is highlighted for its role in continuous glucose monitoring devices and for characteristics often associated with stable, dividend paying healthcare companies. This is prompting some investors to reassess how it fits into diversified portfolios.
See our latest analysis for Abbott Laboratories.
At a share price of US$95.84, Abbott Laboratories has seen short term share price gains, with a 7 day share price return of 5.62% and a 30 day share price return of 5.24%. This follows a weaker patch that includes a 90 day share price return that declined 7.45% and a year to date share price return that declined 22.83%, while the 1 year total shareholder return declined 26.67%. This indicates that recent momentum is rebuilding from a lower base.
If this kind of index reshuffle has you rethinking your exposure to healthcare technology, it could be a good moment to scan other opportunities through the 40 healthcare AI stocks
Bulls point to Abbott Laboratories’ role in glucose monitoring, growing GLP-1 usage and dividends, while bears focus on recent share price declines and index demotion. Which side do the current valuation metrics support?
Most Popular Narrative: 18% Undervalued
Compared with the most followed fair value estimate of $116.54, Abbott Laboratories at $95.84 is priced at a clear discount, which is drawing attention to the assumptions behind that gap.
The analysts have a consensus price target of $116.54 for Abbott Laboratories based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $135.0, and the most bearish reporting a price target of just $92.0.
Want to see what has to happen for Abbott Laboratories to reach that fair value? The narrative leans on steady revenue growth, rising margins and a richer earnings multiple. Curious which exact targets analysts are baking in and how long they think the ramp takes? The full narrative sets out the numbers in black and white.
Result: Fair Value of $116.54 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on Abbott Laboratories managing pressure on diagnostics pricing and utilization, as well as inflation and higher debt costs that could affect future earnings power.
Find out about the key risks to this Abbott Laboratories narrative.
Next Steps
With mixed signals around Abbott Laboratories, do you want to rely only on the headline story or weigh the full picture for yourself? Take a closer look at the 5 key rewards and 2 important warning signs
Looking for more investment ideas beyond Abbott Laboratories?
If Abbott Laboratories has you thinking harder about where to put your next dollar, do not stop at one stock. Use the Simply Wall St Screener to surface fresh ideas that fit your approach.
- Target potential value opportunities by scanning our list of 45 high quality undervalued stocks that pair quality fundamentals with prices below many investors' expectations.
- Prioritize resilience and sleep easier at night by focusing on companies highlighted in the 74 resilient stocks with low risk scores with stronger risk profiles.
- Hunt for potential future standouts before they hit the spotlight using the screener containing 18 high quality undiscovered gems tailored to lesser known stocks with solid fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com